National Cancer Institute 11324545

TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors

This award funds research to enhance liver-directed radiotherapy combined with immune checkpoint blockade using TLR5 activation to treat liver metastasis and abscopal tumors. It supports mechanistic and translational studies in cancer immunotherapy, funded by the National Cancer Institute.

Description

The project involves enhancing liver-directed radiotherapy and immune checkpoint blockade using TLR5 pathway activation. The work is in the context of cancer treatment, specifically liver metastasis. All components of the therapy are in clinical use, supporting feasibility. The project aims to address the control of liver metastasis and abscopal tumors through immunotherapy. The research includes mechanistic studies and translational relevance in human tumors. The award is funded by the National Cancer Institute. The project is part of a multi-year effort with a budget starting June 2026.

View original record